Welcome to BioMarket Group!

Partneringreview 2006 - Therapy area (volume 2)

Additional Information

Published Date Feb 1, 2006
Special Offer No
Pages 1802
PDF Fact Sheet View Fact Sheet for the report Partneringreview 2006 - Therapy area (volume 2) in PDF format.
Published on Date No
Format No
Publisher N/A
Product Line No
Full Title No

Availability: In stock

$2,495.00

Quick Overview

Identify the latest dealmaking trends in your area
Request free sample pages from Partneringreview 2006 - Therapy area (volume 2)

Partneringreview 2006 – Volume 2: Therapy area provides an in depth view into the deals and alliances by therapeutic area announced in 2005, in a clear and accessible format.


The report reviews over 2,600 deal announcements in therapeutic areas - oncology, infectious disease, cardiovascular, circulatory, central nervous system, autoimmune, inflammation, metabolism, respiratory, gastrointestinal, musculoskeletal, sensory organ, oral health, genitourinary, gynecology, dermatology, blood system, lymphatic system, and accident/hospital/trauma.


Each sector is further divided to analyze deals by company, industry sector, and stage of development. Every deal is fully categorized, includes a detailed description, and includes financials such as headline value, upfront and milestone payments, where disclosed.


Each deal is annotated with a deal number, such as #43. This number links to the full deal in the deal listing at the rear of each report. When using the PDF format in Acrobat Reader, simply click on the number to move around the report.


All the year’s deals at a glance.


Want to know what your competitors are doing? Want to benchmark your deals against others in your therapeutic area or see how the finances of different deal types compare? Partneringreview 2006 brings all the 2005’s deals into focus in one place.Partneringreview is a comprehensive summary of the year’s deal announcements in a clear and accessible printable format. Every deal entry includes financial information where disclosed, such as headline values and upfront and milestone payments. A new addition of an overview of financings from investors is also included in this latest edition.

Request free sample pages from Partneringreview 2006 - Therapy area (volume 2)

Other selected research from the 'Business Development' category:


Partneringdesk Solvay S.A. and Company Deals Briefing
Comprehensive summary of the last 5 years of deal-making by the industry’s top 50 pharmaceutical and biotech companies. Learn More


Pre-clinical Stage Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, 2nd edition
The Pre-clinical Stage Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the pre-clinical stage partnering agreements entered into by the worlds leading biopharma companies Learn More

Other selected research from the 'Autoimmune & Inflammation' category:


Stakeholder Opinions: Physician perception of biologics in autoimmune disease - Targeted detailing is the key to success
Opinion from 540 physicians including rheumatologists, dermatologists and gastroenterologists Learn More


Juvenile Arthritis - A Niche In The Market
Juvenile arthritis is the next indication due for approval for blockbuster biologic therapies Remicade (infliximab) and Humira (adalimumab). Pediatric rheumatology is a growing specialty that offers high unmet need in terms of effective well-tested treatments. Rheumatic diseases remain a significant cause of chronic illness in children, with juvenile arthritis one of the most prevalent types. Learn More

Other selected research from the 'Cardiovascular' category:


Statins: The World Market 2010-2025
The world statins market is facing rapid change. From 2010 onwards, there will be major patent expires - most notably for Lipitor - maturity of products, and rising competition from generic alternatives. Learn More


Global Cardiovascular Drugs Market 2009-2024
The years 2011 to 2015 will mark a period of high volatility in the cardiovascular market as key products - including blockbusters Plavix and Lovenox - face patent expiry. What types of therapeutic agent will enter the market from 2009 onwards, and what are their sales prospects? Learn More

Other selected research from the 'Dermatology' category:


Dermatological Drugs: World Market 2011-2026
how you can see the future of the industry and market
Would you like to know how the industry and market for dermatological drugs will develop? There will be trends...
Learn More


Partneringreview 2006 Vol 2 Ch 1: Oncology
Identify the latest dealmaking trends in your field Learn More

Other selected research from the 'Gastroenterology' category:


Commercial and Pipeline Perspectives: Upper GI Disorders - Life Cycle Management Key as Generics and OTC Threaten Growth
The blockbuster PPI class in the US has been exposed to both generic and OTC competition. The impact of these events will shape the dynamics of the PPI market in the near and medium term, as the marketers of PPIs fight to maintain patent protection, prescription status, and formulary positioning. Meanwhile, a new generation of therapies is in development: a new class of fast acting APAs. Learn More


Partneringreview 2006 - Therapy area (volume 2)
Identify the latest dealmaking trends in your area Learn More

Other selected research from the 'Infectious diseases' category:


Commercial Insight: Hepatitis B and C - Awaiting New Developments
The launch of the pegylated interferons has had a dramatic effect on the market for hepatitis treatments, with the improvements in side-effect profile and efficacy leading to significant drug switching. Companies involved in this sector need to reassess their competitive position and understand the new dynamics of this sector. Learn More


Commercial Perspectives: Hepatitis B and C - The Chinese Way?
Along with China`s growing economy, the need for improved healthcare infrastructure and modern pharmaceuticals has attracted many Western manufacturers. One immediate opportunity is the region`s high proportion of global chronic Hepatitis B and C. Antivirals such as lamivudine and adefovir compete not only against Zadaxin and interferons, but also established traditional remedies. Learn More

Other selected research from the 'Metabolic disorders' category:


Antidiabetics market forecast
Datamonitor expects the antidiabetics market to grow to $34.8 billion in 2019 for the seven major markets. Januvia will become the leading franchise from 2012 after patent expiry of... Learn More


Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
Datamonitor expects the antidiabetics market to grow to $34.8 billion in 2019 for the seven major markets. Januvia will become the leading franchise from 2012 after patent expiry of... Learn More

Other selected research from the 'Neurological disorders' category:


The Global Market for Sleep-Wake Disorders, 2005-2012: Trends, Opportunities, and Insights in a High-Value CNS Therapy Area
The scope of the report comprises up-to-date coverage of epidemiological, aetiological, and therapeutic data related to sleep-wake disorders. Learn More


Alzheimer's Disease: Current Treatment Practices and Opportunities 2010
This report presents the findings of a comprehensive survey of current clinical practices in the treatment of Alzheimer’s Disease (AD). Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Breast Cancer, Lymphoma and Apoptosis
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Lymphoma and by the mechanism/target/effect of Apoptosis. Learn More


Triple Analysis: Pancreatic Cancer, Prostate Cancer and Antibodies
This triple analysis focuses on cancer drug development strategies in both Pancreatic Cancer and Prostate Cancer and by the compound strategy of Antibodies. Learn More

Other selected research from the 'Pulmonary & Respiratory' category:


Stakeholder Opinions: Pulmonary Arterial Hypertension clinical community builds order from chaos
Despite an explosion in the number of drugs and treatment strategies available, pulmonary arterial hypertension is still a rapidly fatal condition for a small, hard to identify patient group. Learn More


Stakeholder Perspectives: Pulmonary Arterial Hypertension - A small market gets big attention
Datamonitor expects the global pulmonary arterial hypertension (PAH) market to grow from $636m in 2004 to just over $2 billion by 2014, as new product and formulation launches in the US and a healthy late-stage pipeline drive sales growth. With this increased interest, combined with increased awareness and R&D activity, treatment for this orphan disease is set to enter a new era Learn More

Other selected research from the 'Reproduction' category:


Partneringreview 2006 Vol 2 Ch 11: Genitourinary/Gynecology (PR06V2C11)
Identify the latest dealmaking trends in your field Learn More


Stakeholder Opinions: Female Sexual Dysfunction - Results from Datamonitors 2005 physician survey
Patients in a clinical population receive drug and non-drug therapy for female sexual dysfunction, yet a third remain refractory to treatment, highlighting a need for a formally approved product for FSD. There is a low level of satisfaction with the classification guidelines, further limiting diagnosis, already hampered by embarrassment, lack of physician awareness and an unclear referral system. Learn More

Other selected research from the 'Other' category:


Partneringreview 2006 Vol 2 Ch 10: Sensory Organ/Oral Health (PR06V2C10)
Identify the latest dealmaking trends in your field Learn More


Interstitial Cystitis - Few Treatments, Poor Outcome
Interstitial cystitis (IC) is considered a rare disorder and poor understanding of the underlying causes of the disorder have made diagnosis and management difficult. Moreover, this has impacted on the development of effective drugs for this disorderthere are few available treatments for IC and as a result, significant unmet needs exist. Learn More

Other selected research from the 'Markets' category:


Pharmaceuticals in Japan
Pharmaceuticals in Japan industry profile is an essential resource for top-level data and analysis covering the pharmaceuticals industry. Learn More


Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
This report explores the major types of adaptive design and their role in dose-finding. The report investigates seamless Phase 2/3 trials and adaptive trials in pharmacogenomics, assesses the logistical implications of adaptive trial implementations and reviews the current regulatory standpoints of the FDA and EMEA. Learn More